Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Western Asia has been on the rise in recent years, driven by several factors.
Customer preferences: Patients in Western Asia suffering from autoimmune diseases and those who have undergone organ transplantation are the primary consumers of immunosuppressants. These patients require medication to suppress the immune system, which helps prevent rejection of transplanted organs or tissues and control the symptoms of autoimmune diseases.
Trends in the market: The market for immunosuppressants in Western Asia has been growing steadily due to an increase in the prevalence of autoimmune diseases and organ transplantation. The growing population of elderly people in the region is also contributing to the rising demand for immunosuppressants. Additionally, the development of new and effective immunosuppressant drugs has led to an increase in the number of patients opting for treatment.
Local special circumstances: The healthcare infrastructure in Western Asia is not as developed as in other regions, which can pose challenges for patients seeking treatment. However, the region has been investing in improving healthcare facilities and increasing access to medication. The high cost of immunosuppressants is also a challenge for patients, but some countries in Western Asia have implemented government-funded healthcare programs to provide affordable medication to patients in need.
Underlying macroeconomic factors: The economic growth and increasing disposable income in Western Asia have led to an increase in healthcare spending. This has allowed patients to access better healthcare facilities and medication, including immunosuppressants. The region’s strategic location has also led to an increase in medical tourism, which has contributed to the growth of the immunosuppressants market. Additionally, the region’s favorable regulatory environment and increasing investments in research and development have led to the development of new and innovative immunosuppressant drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
